Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
Gemcitabine resistance is currently the main problem of chemotherapy for advanced pancreatic cancer patients. The resistance is thought to be caused by altered drug metabolism or reduced apoptosis of cancer cells. However, the underlying mechanism of Gemcitabine resistance in pancreatic cancer remai...
Saved in:
Main Authors: | Feng Shao (Author), Mei Huang (Author), Futao Meng (Author), Qiang Huang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2018-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma
by: Zhijun Xiao, et al.
Published: (2021) -
LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma
by: Fan Yang, et al.
Published: (2018) -
SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling
by: Hao Yu, et al.
Published: (2024) -
Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma
by: Julie Schnipper, et al.
Published: (2020) -
Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma
by: Andrea N. Riner, et al.
Published: (2024)